CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

Macrophage MST1/2 Disruption Impairs Post-Infarction Cardiac Repair via LTB4 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study Systems of Care for ST-Segment–Elevation Myocardial Infarction: A Policy Statement From the American Heart Association ST-Segment Elevation Myocardial Infarction Patients in the Coronary Care Unit Is it Time to Break Old Habits? Complete Revascularization Versus Culprit Lesion Only in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A DANAMI-3-PRIMULTI Cardiac Magnetic Resonance Substudy Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials Another Nail in the Coffin for Intra-Aortic Balloon Counterpulsion in Acute Myocardial Infarction With Cardiogenic Shock

Clinical Trial2018 Jun;200:17-23.

JOURNAL:Am J Cardiol. Article Link

An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial

Lopes RD, Vora AN, Liaw D et al. Keywords: apixaban; vitamin K antagonist; aspirin; placebo; ACS; PCI;

FULL TEXT PDF